COMMUNIQUÉS West-GlobeNewswire

-
Adagene to Present at Jefferies Global Healthcare Conference 2025
27/05/2025 -
BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor
27/05/2025 -
Evaxion announces business update and first quarter 2025 financial results
27/05/2025 -
Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases
27/05/2025 -
SciSparc Announces Publication of Japanese Patent Application
27/05/2025 -
ZLNA – New registered share capital
27/05/2025 -
Disclosure of Shareholding – Gjelsten Holding AS
27/05/2025 -
Novartis announces commencement of tender offer to acquire Regulus Therapeutics
27/05/2025 -
Theriva™ Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline Data from the VIRAGE Phase 2b Trial of VCN-01 in Metastatic Pancreatic Cancer
27/05/2025 -
Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer
27/05/2025 -
DeepView® System Achieves 95.3% Accuracy Evaluation as Published in Burns Journal
27/05/2025 -
Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial
27/05/2025 -
Emory Healthcare Researchers Use Dynamic Digital Radiography to Compare Shoulder Improvement of Two Surgical Interventions for Massive Irreparable Rotator Cuff Tears
27/05/2025 -
NeurAxis to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
27/05/2025 -
Nautilus Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
27/05/2025 -
ORYZON to Provide Corporate Progress Updates at Several Events in May-June
27/05/2025 -
NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study
27/05/2025 -
Hydreight Launches Personalized Genetic Testing and Wellness Solution on VSDHOne Platform
27/05/2025 -
Immutep’s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma
27/05/2025
Pages